BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Daval International Limited Awarded Orphan Drug Designation for Motor Neurone Disease Treatment


11/9/2009 8:58:23 AM

LONDON, November 9 /PRNewswire/ -- Following the provision of clinical and scientific data to the US Food and Drug Administration (FDA), privately owned UK company Daval International Limited (http://www.davalinternational.com) has been informed that its innovative anti-inflammatory agent AIMSPRO(R) has been awarded an Orphan-Drug designation for the treatment of Amyotrophic Lateral Sclerosis (ALS).

ALS, also known as Lou Gehrig's disease, is the most common form of Motor Neurone Disease. AIMSPRO has already achieved TGA Orphan Status in Australia for the treatment of both ALS and Krabbe Leukodystrophy (Krabbe's disease). Approaches have been made to Daval to conduct an international, multi-centre, clinical trial to determine whether ALS patients can be seen to benefit from the medication under double-blind conditions.

AIMSPRO is a new generation biological medicine which is sourced and manufactured in Australia with a TGA export listing. It is derived from hyperimmune caprine serum and is currently under Phase II trialing in Europe for Scleroderma and for bladder dysfunction in Secondary Progressive Multiple Sclerosis. Both trials are expected to report in the first half of 2010.

The veterinary form of the product, Ceremben(R) has shown efficacy, safety and tolerability in horses. The Australian regulator, the APVMA, has recently awarded Ceremben a permit enabling promotion and sales to Veterinary Surgeons for the treatment of equine endotoxemia.

CONTACT: Dr. Bryan Youl. Managing Director(Clinical), +44(0)7793526096 &
Brian Quick. Chairman, +44(0)7764828114



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES